Rj. Erdtsieck et al., TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS WITH A COMBINATION OF GROWTH-HORMONE AND PAMIDRONATE - A PLACEBO-CONTROLLED TRIAL, Clinical endocrinology, 43(5), 1995, pp. 557-565
OBJECTIVE It is known that growth hormone can induce accelerated bone
turnover in GH deficient people as well as healthy elderly people. In
this study we examined the effect of recombinant human GH (rhGH) on bo
ne mineral mass and bone turnover in the presence of the bone resorpti
on inhibiting agent, pamidronate. Effects on body composition were als
o studied. METHODS Twenty-one post-menopausal osteoporotic women were
treated with the bisphosphonate pamidronate during 12 months. During t
he initial 6 months rhGH (0.0675 IU/kg, 3 times/week) was administered
in a placebo controlled fashion (10 vs 11 patients). MEASUREMENTS Bon
e mineral content (BMC) of the lumbar spine and femoral neck was measu
red with dual-energy X-ray absorptiometry and BMC of the distal and pr
oximal forearm with single-photon absorptiometry. Body composition was
measured with bioelectrical impedance and total body dual-energy X-ra
y absorptiometry. Serum IGF-l and biochemical indices of bone turnover
were also measured. RESULTS The group treated with rhGH showed a two
to three-fold increase in serum IGF-l levels. No effects on bone miner
al mass were observed in the group treated with rhGH, either after the
initial 6 months of treatment with rhGH or after the total period of
12 months. in women treated with pamidronate, however, a consistent in
crease of about 5% at the lumbar spine and somewhat less in the distal
forearm was reached from 6 months onwards. In neither group was any c
hange observed in BMC at the femoral neck or forearm. Compared to base
line, the biochemical measurements of bone turnover showed a decrease
of about 50% in the pamidronate treated group, but this effect was blu
nted in the group additionally treated with rhGH. The body composition
measurements showed clear effects of rhGH administration: a decrease
in fat mass of about 5% and an increase in lean body mass of about 3%.
However, these effects disappeared after the treatment with rhGH was
stopped and both fat mass and lean body mass returned to initial value
s. CONCLUSIONS The present study suggests that treatment with rhGH blu
nted both the pamidronate induced accumulation of bone mineral mass an
d the reduction of biochemical markers of bone turnover. Furthermore,
the positive effect of rhGH on body composition disappears completely
after cessation of treatment with rhGH.